APREA THERAPEUTICS INC (APRE) Stock Analyst Earnings Estimates
NASDAQ:APRE - Nasdaq - US03836J2015 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 583.23K | 1.366M 134.21% | 918K -32.80% | 918K | 969K 5.56% | 11.06M 1,041.38% | 32.375M 192.72% | 94.492M 191.87% | 186.21M 97.06% | 326.77M 75.48% | |||
| EBITDA YoY % growth | -37.44M 29.06% | -113.39M -202.86% | -15.465M 86.36% | -15.81M -2.23% | -17.85M -12.90% | -20.196M -13.14% | -24.99M -23.74% | -24.684M 1.22% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -37.45M 29.09% | -113.39M -202.78% | -15.472M 86.36% | -16.709M -8.00% | -19.57M -17.12% | -20.956M -7.08% | -23.57M -12.48% | -19.967M 15.29% | 1.718M 108.60% | 54.001M 3,043.25% | 140.74M 160.62% | 266.71M 89.51% | |
| Operating Margin | N/A | N/A | -2,652.81% | -1,223.22% | -2,131.78% | -2,282.78% | -2,432.42% | -180.53% | 5.31% | 57.15% | 75.58% | 81.62% | |
| EPS YoY % growth | -26.26 -933.86% | -30.12 -14.70% | -3.99 86.75% | -2.60 34.90% | -1.52 41.53% | -1.77 -16.52% | -0.63 64.27% | -0.52 17.74% | 2.22 527.45% | 3.65 64.22% | 4.81 31.84% | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.70 23.87% | -0.74 -9.99% | -0.41 29.92% | -0.44 30.91% | -0.46 33.96% |
| Revenue Q2Q % growth | 170.003K 1,114.31% | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | -4.488M -22.36% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.908M -60.76% | -4.897M -55.48% | -5.109M -32.81% | -5.536M -35.11% | -5.749M 2.69% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.64 25.58% | -0.76 | 0.12 | 15.78% |
| Q2 2024 Q2Q % growth | -0.58 33.33% | -0.65 | 0.07 | 10.45% |
| Q1 2024 Q2Q % growth | -0.67 50.00% | -0.79 | 0.12 | 15.41% |
| Q4 2023 Q2Q % growth | -0.92 | -0.79 | -0.13 | -16.63% |
| Q3 2023 Q2Q % growth | -0.86 64.17% | -1.19 | 0.33 | 27.54% |
| Q2 2023 Q2Q % growth | -0.87 95.56% | -1.45 | 0.58 | 40.14% |
| Q1 2023 Q2Q % growth | -1.34 81.39% | -1.54 | 0.20 | 12.71% |
| Q4 2022 Q2Q % growth | -0.92 87.22% | -3.14 | 2.22 | 70.72% |
| Q3 2022 Q2Q % growth | -2.40 73.33% | -5.61 | 3.21 | 57.22% |
| Q2 2022 Q2Q % growth | -19.60 -104.17% | -7.65 | -11.95 | -156.21% |
| Q1 2022 Q2Q % growth | -7.20 -1,465.22% | -7.75 | 0.55 | 7.12% |
| Q4 2021 Q2Q % growth | -7.20 -886.30% | -8.98 | 1.78 | 19.79% |
| Q3 2021 Q2Q % growth | -9.00 -1,451.72% | -9.23 | 0.23 | 2.50% |
| Q2 2021 Q2Q % growth | -9.60 -1,130.77% | -9.54 | -0.06 | -0.66% |
| Q1 2021 Q2Q % growth | -0.46 -2.22% | -0.50 | 0.04 | 8.43% |
| Q4 2020 Q2Q % growth | -0.73 -14.06% | -0.66 | -0.07 | -11.39% |
| Q3 2020 Q2Q % growth | -0.58 89.04% | -0.78 | 0.20 | 25.18% |
| Q2 2020 Q2Q % growth | -0.78 | -0.61 | -0.17 | -26.92% |
| Q1 2020 Q2Q % growth | -0.45 | -0.58 | 0.13 | 22.26% |
| Q4 2019 Q2Q % growth | -0.64 | -0.41 | -0.23 | -56.86% |
| Q3 2019 Q2Q % growth | -5.29 | -4.02 | -1.27 | -31.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 354.62K 11.17% | 229.5K | 125.12K | 54.52% |
| Q2 2024 Q2Q % growth | 562K 124.80% | 51K | 511K | 1,001.96% |
| Q4 2023 Q2Q % growth | 14K | 112.2K | -98.2K | -87.52% |
| Q3 2023 Q2Q % growth | 319K | 84.997K | 234.003K | 275.31% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 6.89% |
| Revenue | 11.11% | N/A | 0% | 8.07% |